Table 3.
Top 30 biological pathways enriched by 19 differentially expressed miRNAs in EGFR-mutated compared to EGFR wild-type lung adenocarcinoma.
| KEGG Pathway | p Values | n1 of miRNAs |
|---|---|---|
| Hippo signaling pathway | 2.38E–08 | 18 |
| Pathways in cancer | 4.33E–05 | 18 |
| FoxO signaling pathway | 2.38E–08 | 17 |
| Signaling pathways regulating pluripotency of stem cells | 3.84E–07 | 17 |
| PI3K-Akt signaling pathway | 2.44E–04 | 17 |
| Chronic myeloid leukemia | 4.43E–04 | 17 |
| Glioma | 9.11E–04 | 17 |
| T-cell receptor signaling pathway | 1.42E–03 | 17 |
| Regulation of actin cytoskeleton | 1.70E–03 | 17 |
| Neurotrophin signaling pathway | 2.80E–03 | 17 |
| Prolactin signaling pathway | 3.26E–03 | 17 |
| Viral carcinogenesis | 3.26E–03 | 17 |
| MAPK signaling pathway | 3.50E–03 | 17 |
| Non-small cell lung cancer | 3.75E–03 | 17 |
| Thyroid hormone signaling pathway | 3.79E–03 | 17 |
| cAMP signaling pathway | 4.95E–03 | 17 |
| Melanoma | 7.01E–03 | 17 |
| cGMP-PKG signaling pathway | 7.40E–03 | 17 |
| Dorsoventral axis formation | 1.99E–02 | 17 |
| Wnt signaling pathway | 2.59E–02 | 17 |
| B cell receptor signaling pathway | 2.80E–02 | 17 |
| Ubiquitin mediated proteolysis | 2.82E–02 | 17 |
| TGF-beta signaling pathway | 8.42E–08 | 16 |
| Proteoglycans in cancer | 1.36E–07 | 16 |
| Transcriptional misregulation in cancer | 3.26E–07 | 16 |
| Pancreatic cancer | 3.34E–05 | 16 |
| Ras signaling pathway | 8.22E–05 | 16 |
| ErbB signaling pathway | 1.12E–04 | 16 |
| GABAergic synapse | 3.59E–04 | 16 |
| Focal adhesion | 8.84E–04 | 16 |
KEGG, Kyoto Encyclopedia of Genes and Genomes. 1 n, number of miRNAs that enriched each biological pathway. Pathways with p value less than 0.05 and thresholds for predictions greater than 0.8 are listed with the number of affected genes.